Literature DB >> 19464545

Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection.

Jamie F S Mann1, Eisin Shakir, Katharine C Carter, Alexander B Mullen, James Alexander, Valerie A Ferro.   

Abstract

Previous studies, using parenteral administration of antigen in lipid vesicles, have indicated a possible role for vesicle size in determining the Th1/Th2 bias of the resulting immune response. We have also demonstrated that the incorporation of bile salts into lipid vesicles (bilosomes) allows successful induction of mucosal and systemic immunity via the oral route. The following study was therefore carried out to determine whether size could also influence the Th1/Th2 bias in the immune response to bilosome entrapped influenza A antigen containing haemagglutinin administered by the oral route in the mouse and whether this could influence the disease process in the classical ferret model of disease. Consequently we produced two formulations of influenza A antigen entrapped in bilosomes: BV3 which contained a single population (range 10-100 nm, Z-average diameter 250 nm) and BV which had two populations (60-350 and 400-2,500 nm, Z-average 980 nm). Following oral vaccination of BALB/c mice, BV was found to generate an immune response that had a significantly greater Th1 bias than BV3 as measured by serum IgG2a production and antigen-induced spleen cell IFN-gamma production. In the traditional infection challenge model (ferrets) vaccination with BV (large) vesicles resulted in greater protection in terms of symptom-score and a higher responder number. However, both oral vaccine formulations were an improvement on intramuscular administration in terms of higher antibody production, lower temperatures, and reduced symptoms over time, post-infection. The results presented here demonstrate that oral vaccine formulations can be physically modified to manipulate resultant immune responses following vaccination and consequently can be designed to enhance the effectiveness of candidate vaccine antigens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464545     DOI: 10.1016/j.vaccine.2009.03.040

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  47 in total

1.  Development and evaluation of chitosan-coated liposomes for oral DNA vaccine: the improvement of Peyer's patch targeting using a polyplex-loaded liposomes.

Authors:  Sunee Channarong; Wanpen Chaicumpa; Nuttanan Sinchaipanid; Ampol Mitrevej
Journal:  AAPS PharmSciTech       Date:  2010-12-31       Impact factor: 3.246

Review 2.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

Review 3.  Effect of vaccine administration modality on immunogenicity and efficacy.

Authors:  Lu Zhang; Wei Wang; Shixia Wang
Journal:  Expert Rev Vaccines       Date:  2015-08-27       Impact factor: 5.217

4.  Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design.

Authors:  Xinran Li; Brian R Sloat; Nijaporn Yanasarn; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2010-12-21       Impact factor: 5.571

Review 5.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

6.  Consideration of the efficacy of non-ionic vesicles in the targeted delivery of oral vaccines.

Authors:  Jitinder S Wilkhu; Sarah E McNeil; David E Anderson; Yvonne Perrie
Journal:  Drug Deliv Transl Res       Date:  2014-06       Impact factor: 4.617

7.  Surface-modified P(HEMA-co-MAA) nanogel carriers for oral vaccine delivery: design, characterization, and in vitro targeting evaluation.

Authors:  Matilde Durán-Lobato; Brenda Carrillo-Conde; Yasmine Khairandish; Nicholas A Peppas
Journal:  Biomacromolecules       Date:  2014-07-02       Impact factor: 6.988

Review 8.  Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.

Authors:  John C Kraft; Jennifer P Freeling; Ziyao Wang; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2013-11-25       Impact factor: 3.534

Review 9.  Modulating the immune system through nanotechnology.

Authors:  Tamara G Dacoba; Ana Olivera; Dolores Torres; José Crecente-Campo; María José Alonso
Journal:  Semin Immunol       Date:  2017-10-09       Impact factor: 11.130

Review 10.  Enhancing oral vaccine potency by targeting intestinal M cells.

Authors:  Ali Azizi; Ashok Kumar; Francisco Diaz-Mitoma; Jiri Mestecky
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.